Contact
searchSearch
HMP Global
Login
Quiz

What is the "most underutilized medication" in bipolar disorder treatment?

Rakesh Jain, MD, MPH, RD
08/12/2024

Related Content

Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
Postpartum mother holding child
News
Postpartum Psychosis Should Be a Distinct Diagnosis, Experts Recommend
11/19/2025
Maria Mantas
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is calling for postpartum psychosis (PP) to be recognized as a distinct diagnostic category in the DSM-5 and ICD-11.
An expert consensus panel is...
11/19/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use